Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$673.06M+7188.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arthur T. Sands
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Beta
- 1.82
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 9.19
Financials
Revenue
$673.06M+7189.0%Net Income
$549.81MEBITDA
$565.55MFree Cash Flow
$614.24MEPS (diluted)
$4.73Shares Outstanding (diluted)
116.15M+3594.8%Operating Expenses
$113.61MCash & Debt
$1.05BReturn of Capital
$0.00Revenue by Segment (annual)
$83.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $83.98M | $-264.46M | $-3.05 |
| 2024 | $54.55M | $-193.57M | $-2.88 |
| 2023 | $76.99M | $-143.95M | $-2.65 |
| 2022 | $38.63M | $-180.36M | $-3.71 |
| 2021 | $29.75M | $-117.19M | $-2.73 |
| 2020 | $17.82M | $-43.24M | $-2.76 |
| 2019 | $31.11M | $-21.70M | $-0.56 |
| 2018 | $37.45M | $-9.43M | $-0.59 |
Valuation
NRIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-8.70%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·11d ago·Positive
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 da
View source ↗ - Newszacks.com·12d ago·Neutral
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
…x and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…ent and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by a…
View source ↗ - Newsseekingalpha.com·38d ago·Positive
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
View source ↗ - Newsseekingalpha.com·39d ago·Positive
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·45d ago·Neutral
Here's Why You Should Add NRIX Stock to Your Portfolio Now Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·46d ago·Positive
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Wed, Jan 27(in 3 months)
Consensus estimate $-0.46 per share
Typical surprise -0.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Oct 12$4.73 vs $-0.60beat
- Thu, Jul 9$-0.81 vs $-0.72miss
- Wed, Apr 8$-0.79 vs $-0.76miss
- Wed, Jan 28$-0.82 vs $-0.84beat
- Thu, Oct 9$-1.03 vs $-0.84miss
- Wed, Jul 9$-0.52 vs $-0.71beat
Estimates and results for NRIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRIX officers and directors.
- Bought
- —
- Sold
- $3.8m
0 trades
28 trades
- Hansen Gwennsold
- Gregory Julia Psold
- Ring Christinesold
- Ring Christinesold
- Ring Christinesold
- Hansen Gwennsold
- Hansen Gwennsold
- Hansen Gwennsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRIX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.